Model-based projections of the population-level impact of hepatitis A vaccination in Mexico

References

• Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 1999; 61:825 - 9; PMID: 10586919
   PubMed Web of Science ®Google Scholar
• Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine 2000; 18:Suppl 1 S57 - 60; http://dx.doi.org/10.1016/S0264-410X(99)00466-1; PMID: 10683550
   PubMed Web of Science ®Google Scholar
• Shouval D, Mikhaylov M, Van Herck K, Hepatitis A. Vaccines – Impact of Universal Childhood Vaccination Programmes. European Gastroenterology & Hepatology Review 2011; 7:77 - 83
   Google Scholar
• Lazcano-Ponce E, Conde-Glez CJ, Rojas R, Deantonio R, Romano L, Cervantes Y, et al. Hepatitis A seroprevalence in children and adults in Mexico: endemicity and implications for hepatitis A vaccination. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 51st Annual Meeting, Chicago, USA, 17-20 September. 2011.
   Google Scholar
• Valdespino JL, Ruiz-Gómez J, Olaiz-Fernández G, Arias-Toledo E, Conde-González CJ, Palma O, et al. Seroepidemiology of hepatitis A in Mexico. A detector of social inequity and monitor of immunization policies. Salud Publica Mex 2007; 49:S377 - 85; http://dx.doi.org/10.1590/S0036-36342007000900009
   Web of Science ®Google Scholar
• Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28:6653 - 7; http://dx.doi.org/10.1016/j.vaccine.2010.08.037; PMID: 20723630
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics. Havrix Junior Monodose vaccine. 2011 [cited 2011 Nov. 3]; Available from: URL:http://www.medicines.org.uk/emc/medicine/2040/SPC/
   Google Scholar
• Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011; 83:1885 - 91; http://dx.doi.org/10.1002/jmv.22200; PMID: 21915861
   PubMed Web of Science ®Google Scholar
• Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother 2012; 8:313 - 7; PMID: 22327499
   PubMed Web of Science ®Google Scholar
• Chodick G, Heymann AD, Ashkenazi S, Kokia E, Shalev V. Long-term trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization program. J Viral Hepat 2008; 15:Suppl 2 62 - 5; http://dx.doi.org/10.1111/j.1365-2893.2008.01032.x; PMID: 18837837
   PubMed Web of Science ®Google Scholar
• Vacchino MN. Incidence of Hepatitis A in Argentina after vaccination. J Viral Hepat 2008; 15:Suppl 2 47 - 50; http://dx.doi.org/10.1111/j.1365-2893.2008.01029.x; PMID: 18837834
   PubMed Web of Science ®Google Scholar
• Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58:1 - 27; PMID: 19478727
   PubMedGoogle Scholar
• Shouval D. The Immunological Basis for Immunization Series. Module 18: Hepatitis A. 2011 Available from: URL:http://whqlibdoc.who.int/publications/2011/9789241501422_eng.pdf
   Google Scholar
• Sistema Nacional de Informacion en Salud. Mexican surveillance. CENSIA 2004-2008. 2011 Available from: URL:http://www.sinais.salud.gob.mx/estadisticasportema.html
   Google Scholar
• Gutiérrez G, Pérez-Cuevas R, Levy S, Reyes H, Acosta B, Cantón SF, et al. Strengthening preventive care programs: a permanent challenge for healthcare systems; lessons from PREVENIMSS México. BMC Public Health 2010; 10:417; http://dx.doi.org/10.1186/1471-2458-10-417; PMID: 20626913
   PubMed Web of Science ®Google Scholar
• Centro Nacional para la Salud de la Infancia y la Adolescensia (CENSIA). Encuestas de cobertura de vacunacion 2004-2010. 2010 [cited 2011 Nov. 16]; Available from: URL:http://www.censia.salud.gob.mx/descargas/infancia/2010/2.1_REC08-09INSPENC06-10.PDF
   Google Scholar
• Ellis A, Rüttimann RW, Jacobs RJ, Meyerhoff AS, Innis BL. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev Panam Salud Publica 2007; 21:345 - 56; http://dx.doi.org/10.1590/S1020-49892007000500002; PMID: 17761046
   PubMed Web of Science ®Google Scholar
• Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 2007; 42:152 - 60; http://dx.doi.org/10.1007/s00535-006-1984-x; PMID: 17351805
   PubMed Web of Science ®Google Scholar
• Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of Hepatitis A vaccination in Canada. Vaccine 2007; 25(51): 85361):48.
   Google Scholar
• Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med 2000; 154:763 - 70; PMID: 10922271
   PubMed Web of Science ®Google Scholar
• Villa S, Guiscafré H, Martínez H, Muñoz O, Gutiérrez G. Seasonal diarrhoeal mortality among Mexican children. Bull World Health Organ 1999; 77:375 - 80; PMID: 10361753
   PubMed Web of Science ®Google Scholar
• Gutiérrez G, Tapia-Conyer R, Guiscafré H, Reyes H, Martínez H, Kumate J. Impact of oral rehydration and selected public health interventions on reduction of mortality from childhood diarrhoeal diseases in Mexico. Bull World Health Organ 1996; 74:189 - 97; PMID: 8706235
   PubMed Web of Science ®Google Scholar
• Derya A, Necmi A, Emre A, Akgün Y. Decline of maternal hepatitis a antibodies during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg 2005; 73:457 - 9; PMID: 16103622
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Chang SJ, Partridge S, Hollister JC, Kaplan KM, Jensen EH, et al. Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 2002; 21:347 - 8; http://dx.doi.org/10.1097/00006454-200204000-00017; PMID: 12075769
   PubMed Web of Science ®Google Scholar
• Feinstone SM, Gust ID. Hepatitis A vaccine. In: Plotkin SA, OrensteinWA, editors. Vaccines. 3 ed. Philadelphia: WB Saunders; 1999. 650-671.
   Google Scholar
• Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1992.
   Google Scholar
• Van Effelterre TP, Zink TK, Hoet BJ, Hausdorff WP, Rosenthal P. A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization. Clin Infect Dis 2006; 43:158 - 64; http://dx.doi.org/10.1086/505115; PMID: 16779741
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002; 109:839 - 45; http://dx.doi.org/10.1542/peds.109.5.839; PMID: 11986444
   PubMed Web of Science ®Google Scholar
• Abarca K, Ibánez I, Perret C, Vial P, Zinsou JA. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis 2008; 12:270 - 7; http://dx.doi.org/10.1016/j.ijid.2007.08.006; PMID: 17988917
   PubMed Web of Science ®Google Scholar
• Noskova AV, Gorbunov MA, Pavlova LI, El’shina GA, Sharipova IS, Karpovich LG, et al. [Comparative study of the reactivity, safety and immunogenicity of “Havrix” inactivated hepatitis A vaccine]. Vopr Virusol 2000; 45:42 - 4; PMID: 11200647
   PubMedGoogle Scholar
• Poovorawan Y, Kosuwon P, Sutra S, Theamboonlers A, Vimolket T, Safary A. Comparison of the reactogenicity and immunogenicity of two different dose levels of hepatitis A vaccine in healthy children and adolescents. Asian Pac J Allergy Immunol 1998; 16:111 - 7; PMID: 9876949
   PubMed Web of Science ®Google Scholar